Engineered Polymeric Nanozymes for Targeted Lysosome-Mediated Bacterial Clearance in Tumor Immunotherapy

Study Background and Research Question

Colorectal cancer (CRC) remains among the most prevalent and lethal cancers worldwide, with over 1.9 million new cases and nearly a million deaths annually. Despite advances in immunotherapy, particularly immune checkpoint inhibitors and CD47 blockade, durable responses in CRC are rare, especially when compared with other malignancies such as melanoma or lung cancer. A critical obstacle is the profoundly immunosuppressive tumor microenvironment, shaped in part by tumor-associated macrophages (TAMs) that can facilitate tumor progression and immune evasion.

Emerging evidence implicates Fusobacterium nucleatum (Fn)—an intracellular bacterium that preferentially colonizes CRC tumors—as a driver of this immunosuppressive milieu. Fn persists within macrophages, promoting their polarization toward an M2-like, tumor-supportive state and modulating signaling pathways (e.g., TLR4/NF-κB/S100A9 and CXCL2/CXCR2). The reference study (Yu et al., ACS Nano, 2026) therefore asked: can precise eradication of intramacrophage Fn reprogram the tumor immune landscape and enhance the efficacy of CD47 blockade therapy in CRC?

Key Innovation from the Reference Study

The study introduces a self-activatable polymeric nanozyme system (AS@PMFM) designed for targeted delivery and activation within Fn-infected macrophages. This nanozyme consists of ferrocene-bearing glycopolymers loaded with artesunate (AS), a drug known for its ability to induce autophagy. Key features of this innovation include:

• Mannose receptor-mediated targeting: The nanozyme exploits the overexpression of mannose receptors on M2-like, Fn-infected macrophages to ensure selective uptake.
• Intracellular, self-activating mechanism: Upon endocytosis, the nanozyme responds to elevated hydrogen peroxide (H₂O₂) levels characteristic of the tumor microenvironment, releasing ferrous ions and AS.
• Synergistic ROS amplification: Ferrous ions catalyze Fenton reactions, generating reactive oxygen species (ROS) that are cytotoxic to intracellular bacteria; AS further augments ROS formation and induces autophagic flux.
• Autophagolysosomal colocalization: Artesunate-driven autophagy enhances the delivery of both nanozyme and bacteria to lysosomes, intensifying ROS-mediated bacterial killing.

Methods and Experimental Design Insights

The research employed a multi-tiered experimental approach to dissect both mechanistic and therapeutic outcomes:

• In vitro macrophage infection models: Human and murine macrophages were infected with Fn, polarized to the M2 phenotype, and then treated with the nanozyme. Lysosome labeling in live cells—using Lyso-Tracker Red DND-99—enabled high-resolution visualization of nanozyme-bacteria colocalization and autophagic flux.
• Reactive oxygen species quantification: Intracellular ROS generation was measured post-treatment to confirm Fenton chemistry activation.
• Phenotypic and functional macrophage assays: Flow cytometry, cytokine profiling, and gene expression analyses characterized the shift from M2 to M1 macrophage states after bacterial clearance.
• In vivo efficacy: Both xenograft and orthotopic mouse models of CRC, harboring intracellular Fn, were treated with the nanozyme and anti-CD47 antibodies to evaluate tumor growth, immune landscape remodeling, and survival outcomes.

Key technical steps included the use of advanced fluorescent lysosome probes for live cell imaging. Lyso-Tracker Red DND-99, a highly specific marker for acidic lysosomal compartments, was central to tracking nanozyme and bacterial fate within macrophages, as previously outlined in internal reviews.

Protocol Parameters

• Lyso-Tracker Red DND-99 staining: Live macrophages were incubated with 50–100 nM Lyso-Tracker Red for 30–60 minutes at 37°C prior to imaging, as recommended in best-practice summaries.
• Nanozyme treatment: Macrophages were exposed to AS@PMFM at concentrations optimized for selective cytotoxicity toward intracellular bacteria (typically 5–10 μM artesunate payload).
• Imaging workflow: Fluorescent microscopy was used to track lysosomal distribution and morphology, ensuring co-localization with both nanozyme and bacterial signals in real time.

Core Findings and Why They Matter

The reference study (Yu et al., ACS Nano, 2026) demonstrated several impactful outcomes:

• Selective bacterial eradication: The nanozyme efficiently eliminated intracellular Fn within M2-like macrophages via ROS amplification and autophagy-mediated targeting to lysosomes.
• Macrophage immune reprogramming: Clearance of Fn reversed the immunosuppressive phenotype of infected macrophages and triggered paracrine signaling that promoted M1 polarization in neighboring uninfected macrophages.
• Enhanced immunotherapy efficacy: In both mouse models, combining nanozyme treatment with CD47 blockade led to superior tumor regression and survival compared to monotherapies, attributed to systemic remodeling of the macrophage immune landscape.

These findings underscore the pivotal role of lysosomal function—and its visualization via tools like Lyso-Tracker Red DND-99—in decoding the mechanisms underlying immune evasion and therapy resistance in CRC. The work substantiates that targeting intramacrophage bacterial reservoirs can synergize with immune checkpoint therapies to overcome the immunosuppressive tumor microenvironment. This approach exemplifies a new paradigm for leveraging lysosomal biology in translational cancer research.

Comparison with Existing Internal Articles

Several internal resources have previously highlighted the strategic value of advanced lysosome labeling in live cells for tumor microenvironment studies. For example, the article "Lysosome Tracking: Precision Tools for Tumor Microenvironment Research" discusses the foundational and emerging applications of Lyso-Tracker Red DND-99 in mapping lysosomal dynamics during cancer progression and therapy response. Similarly, "Lyso-Tracker Red DND-99: Precision Lysosome Tracking in Cancer Research" explores the use of this probe in decoding lysosomal membrane behavior underlying therapy resistance. The reference study builds on these insights by operationalizing lysosomal tracking for the real-time evaluation of bacterial clearance and macrophage phenotype transformation in the context of immunotherapy—effectively bridging mechanistic cell biology and translational oncology.

Notably, the detailed protocols and mechanistic rationales for using Lyso-Tracker Red in live cell imaging, as described in internal best-practice articles, are directly applied in the reference research to validate autophagolysosomal targeting and ROS-mediated bacterial killing, reinforcing the translational utility of such probes.

Limitations and Transferability

Despite its novelty, the study has several limitations:

• Model specificity: The experiments are primarily conducted in murine models and cultured macrophages, which may not fully replicate the complexity of human CRC microenvironments.
• Pathogen focus: The strategy centers on Fusobacterium nucleatum, and its applicability to other intracellular pathogens remains to be established.
• Nanozyme safety and pharmacokinetics: While the platform demonstrated efficacy and selectivity in preclinical models, comprehensive toxicity and pharmacokinetic profiling will be needed before clinical translation.
• Lysosomal probe constraints: Lyso-Tracker Red and similar probes are optimized for live cell imaging and are not suitable for fixed tissues; care must be taken to avoid photobleaching and ensure proper probe handling as outlined by the product information.

Transferability to other tumor types or immune contexts will require additional validation, particularly regarding the universality of the mannose receptor-mediated targeting and autophagy-inducing payloads.

Research Support Resources

Researchers aiming to replicate or extend these advanced workflows can leverage high-specificity lysosomal probes for live cell imaging. Lyso-Tracker Red (SKU B8814) from APExBIO is widely utilized for precise lysosome labeling in live cells, supporting visualization of intracellular acidic compartments and facilitating studies of lysosomal distribution, morphology, and activity. When used according to recommended protocols, Lyso-Tracker Red enables rigorous analysis of autophagolysosomal dynamics relevant to bacterial clearance and immune modulation in cancer models.